United Therapeutics Corporation (U2TH34)
Sao Paulo Exchange · Brazil · prices in BRL · close of 15 Oct 2026
Key indicators
| Last close | BRL 135.24 |
|---|---|
| 52-week range | 113.63 – 155.07 |
| Return, 1 month / 3 months | +6.5% / +1.7% |
| Return, 1 year / 3 years | +12.8% / +134.7% |
| Trend | Uptrend |
| RSI (14) | 93 |
| Volatility (1 year) | 23.4% |
| Worst drawdown (1 year) | -17.4% |
| Average daily value traded | 0.02M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
United Therapeutics Corporation is a pharmaceutical company that develops and commercializes therapies for pulmonary arterial hypertension, a condition of high blood pressure in the arteries of the lungs. Its products include prostacyclin-based medicines delivered by infusion, inhalation and other routes, and it also pursues work in organ manufacturing and transplant technologies. The company is based in Silver Spring, Maryland, in the United States, and its medicines reach patients and clinicians in markets around the world.
United Therapeutics Corporation is represented on the Sao Paulo Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code U2TH34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
United Therapeutics Corporation (U2TH34) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 135.24 on 15 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 622 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 12.8% and over the last three months it rose 1.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 49 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 0.2% | ||
| From 52-week high | -12.0% | ||
| Momentum | 42 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 1.7% | ||
| 6-month return | -12.0% | ||
| 12-month return, skipping the last month | 5.9% | ||
| Stability (higher is calmer) | 86 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 23.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.4% | ||
| Liquidity | 30 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M BRL | ||
| Zero-volume days | 83.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +6.5% |
| 3 months | +1.7% |
| 6 months | −12.0% |
| 1 year | +12.8% |
| 3 years | +134.7% |
| 5 years | – |
Signals
| 50-day / 200-day average | 129.33 / 134.91 |
|---|---|
| Golden / death cross (60 days) | Death, 41 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.38 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.